| Company Name: |
Suzhou Meishi Biotechnology Co., Ltd.
|
| Tel: |
1173954148q |
| Email: |
meishipharma@126.com |
| Products Intro: |
Product Name:132031-81-3
CAS:132031-81-3
Purity:99% HPLC Package:1G;5G;10G;100G;1KG;
|
| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:NP-252
CAS:132031-81-3
Package:50mg/RMB 13800;100mg/RMB 17500;25mg/RMB 10600
|
| Company Name: |
CHEMICAL LAND21
|
| Tel: |
82- 2 -783 - 8063 |
| Email: |
sales21@chemicalland21.com |
| Products Intro: |
|
NP 252 manufacturers
- NP-252
-
- $1980.00 / 50mg
-
2024-10-24
- CAS:132031-81-3
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| Product Name: | NP 252 | | Synonyms: | NP 252;2,6-Dimethyl-3-cyclopropylaminocarbonyl-4-(o-nitrophenyl)-1,4-dihydropyridine-5-carboxylic acid octyl ester | | CAS: | 132031-81-3 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | 132031-81-3.mol |  |
| | NP 252 Chemical Properties |
| | NP 252 Usage And Synthesis |
| Description | NP-252 is a calcium channel antagonist potentially for the treatment of angina pectoris and congestive heart failure. The vasoinhibitory effects of NP-252 were significantly stronger than those of nifedipine in canine cerebral artery. NP-252 (10(-7) and 10(-6) M) dose-dependently attenuated nifedipine-resistant Ca(++)-contraction in the presence of STA2 in both canine cerebral and coronary arteries. The inhibitory effect of combined treatment with NP-252 (10(-6) M) and nitroglycerin (10(-6) M) on nifedipine-resistant Ca(++)-contraction in the cerebral artery was additive. In aorta, only NP-252 reduced total La3+ resistant 45Ca binding. However, the increases in bound 45Ca at La3+ resistant sites and 45Ca unidirectional influx due to KCl were inhibited by both NP-252 and nifedipine. |
| | NP 252 Preparation Products And Raw materials |
|